What did Cowen change in its TECH analyst rating on March 17, 2026?

Cowen & Co. **maintained a Buy** on TECH on March 17, 2026, calling a recent sell-off overdone. The note did not include a new price target and positioned the pullback as a buying opportunity for longer-term investors.

How should investors interpret a maintained Buy in the TECH analyst rating?

A maintained Buy means the analyst still favors the stock’s fundamentals but did not raise near-term upside. For TECH, Cowen’s note suggests accumulation on weakness rather than immediate re-rating or a fresh price target.

Did Cowen publish a TECH price target with its March 17, 2026 note?

No. The Cowen summary on March 17, 2026 did not publish an updated TECH price target in the StreetInsider report. Investors should watch for a full research release for any new target.

How does the Meyka grade affect understanding of the TECH analyst rating?

Meyka AI rates TECH with a grade of **B+**, reflecting S&P 500 comparison, sector performance, growth, metrics, and analyst consensus. The grade complements the TECH analyst rating but is not financial advice or a guarantee.

Analyst Ratings

Cowen Maintains Buy on TECH (Bio-Techne Corporation) March 17, 2026

ByHuzaifa Zahoor March 18, 2026March 18, 2026

On March 17, 2026 Cowen & Co. maintained a Buy on Bio-Techne Corporation (TECH), a clear signal in the ongoing TECH analyst rating debate. Cowen said the recent sell-off “looks overdone” and recommended buying on weakness. The note did not update a new price target but framed the pullback as a near-term buying opportunity for long-term investors.